Loading data for SBFMW — first visit, this takes a few seconds.
Sunshine Biopharma Inc. (SBFMW)
NasdaqCM: SBFMW
· Echtzeitkurs · USD
0.04
+0.00 (0.00%)
Zum Schluss: Aug 04, 2026, 7:31 PM
Sunshine Biopharma Inc. (SBFMW) Stock Price, Analysis & Data
0.00% (1D)
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | n/a |
| Umsatz (TTM) | 35.49 Mio |
| Nettogewinn (TTM) | -6.04 Mio |
| Beta | 1.31 |
| EPS (ttm) | -2.21 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | n/a |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | 0 |
| Ø Vol. (20D) | |
| Eröffnung | 0.24 |
| Vortagesschluss | 0.04 |
| Tagesspanne | 0.04 - 0.04 |
| 52-Wk Range | 0.04 - 0.04 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über SBFMW
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calciu...
IPO Datum Jul 17, 2026
Mitarbeiter 50
Börse NasdaqCM
Tickersymbol SBFMW
Website https://sunshinebiopharma.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Sunshine Biopharma 36.31 Mio, ein Anstieg von 4.11% im Vergleich zum Vorjahr (34.87 Mio). Der Gewinn lag bei -5.98 Mio, ein Anstieg von 16.39 %.
Finanzberichte